Organization | The Korean Society of Pediatric Hematology Oncology

The Korean Society of Pediatric Hematology Oncology Report issue

Academic/Hospital Phase 2

Founded: Seoul Korea, Republic of (1993)

Organization Overview

First Clinical Trial

2006

NCT00737685

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (6)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)

busulfan (myleran) (2 trials)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

fludarabine (fludara) (4 trials)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Syndrome (Phase 2)

Wiskott-Aldrich Syndrome (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 6